FindTrial
Sign In

LY3202626

DRUG3 trials

Sponsors

Eli Lilly and Company

Conditions

Alzheimer DiseaseAlzheimer's DiseaseHealthy Volunteers

Phase 1

A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
CompletedNCT02323334
Eli Lilly and CompanyHealthy Volunteers, Alzheimer Disease
Start: 2014-12-31End: 2016-02-29Updated: 2021-04-19

Phase 2

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia
TerminatedNCT02791191
Eli Lilly and CompanyAlzheimer's Disease
Start: 2016-06-16End: 2018-07-02Updated: 2021-04-19
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
CompletedNCT03367403
Eli Lilly and CompanyAlzheimer Disease
Start: 2017-12-18End: 2021-09-21Updated: 2026-03-19

Related Papers

Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for <i>APOE</i> ε4.
2026-08-26
Association of Occipital Amyloid PET Burden with ARIA‐E: Exploratory Analyses in Three Clinical Trials of Donanemab
Alzheimer s & Dementia2025-12-01
Donanemab physiologically based pharmacokinetic model coupled with natural life cycle model for amyloid plaque aggregation to predict target CSF and ISF concentrations associated with amyloid plaque reduction
Alzheimer s & Dementia2025-12-01
Association of Occipital Amyloid PET Burden with ARIA‐E: Exploratory Analyses in Three Clinical Trials of Donanemab
Alzheimer s & Dementia2025-12-01
Regional tau quantification methodologies in early symptomatic participants with presence of tau pathology
Alzheimer s & Dementia2025-12-01
Donanemab exposure‐response in early symptomatic Alzheimer's disease
Alzheimer s & Dementia2025-07-015 citations
Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions2025-07-011 citations
The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.
2025-07-01
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease
JAMA Neurology2025-03-1059 citations
Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.
2024-09-182 citations
Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials
Alzheimer s & Dementia2023-12-014 citations
Bayesian network analysis of BIN1 risk allele and other risk factors and biomarkers of Alzheimer’s disease
Alzheimer s & Dementia2023-12-011 citations
To Assess Mediation Effects of BIN1 Risk Variant rs6733839 and APOE4 on Alzheimer’s disease Pathology
Alzheimer s & Dementia2023-12-011 citations
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
Alzheimer s & Dementia Translational Research & Clinical Interventions2023-07-0116 citations
Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease
Alzheimer s & Dementia2023-06-011 citations
Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease
Clinical Pharmacology & Therapeutics2023-02-1861 citations
Data‐Driven Methods Highlight Early Signals of Tau in Patients Lacking Global Uptake: Facilitating Enrollment in Clinical Trials
Alzheimer s & Dementia2022-12-01
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease
JAMA Neurology2022-10-17229 citations
Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
JAMA Neurology2022-09-12172 citations
Reproducibility of applying multiple statistical analyses to data from the TRAILBLAZER‐ALZ clinical trial of donanemab in early symptomatic Alzheimer's disease
Alzheimer s & Dementia2021-12-013 citations

7 more papers not shown